S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:ARDS

Aridis Pharmaceuticals Stock Forecast, Price & News

$2.39
+0.08 (+3.46%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.27
$2.49
50-Day Range
$2.18
$4.02
52-Week Range
$2.15
$8.47
Volume
70,717 shs
Average Volume
66,494 shs
Market Capitalization
$33.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.12
30 days | 90 days | 365 days | Advanced Chart
Receive ARDS News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Aridis Pharmaceuticals logo

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA.

Headlines

Aridis Pharmaceuticals (NASDAQ:ARDS) Price Target Cut to $10.00
November 11, 2021 |  americanbankingnews.com
Aridis Pharmaceuticals Announces Third Quarter 2021 Results
November 10, 2021 |  finance.yahoo.com
Aridis Pharmaceuticals Inc.
August 5, 2021 |  barrons.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDS
Employees
33
Year Founded
N/A

Sales & Book Value

Annual Sales
$1 million
Book Value
($0.30) per share

Profitability

Net Income
$-22.33 million
Pretax Margin
-7,154.38%

Debt

Price-To-Earnings

Miscellaneous

Free Float
11,510,000
Market Cap
$33.59 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/29/2022

MarketRank

Overall MarketRank

1.84 out of 5 stars

Medical Sector

770th out of 1,391 stocks

Pharmaceutical Preparations Industry

369th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions

Is Aridis Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aridis Pharmaceuticals stock.
View analyst ratings for Aridis Pharmaceuticals
or view top-rated stocks.

How has Aridis Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Aridis Pharmaceuticals' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARDS shares have decreased by 63.0% and is now trading at $2.39.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 5,100 shares, a drop of 67.1% from the October 31st total of 15,500 shares. Based on an average trading volume of 33,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the company's stock are short sold.
View Aridis Pharmaceuticals' Short Interest
.

When is Aridis Pharmaceuticals' next earnings date?

Aridis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Aridis Pharmaceuticals
.

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.94) EPS for the quarter, missing the Zacks' consensus estimate of ($0.51) by $1.43. The firm earned $0.52 million during the quarter.
View Aridis Pharmaceuticals' earnings history
.

What price target have analysts set for ARDS?

3 brokers have issued 12-month price targets for Aridis Pharmaceuticals' shares. Their forecasts range from $10.00 to $19.00. On average, they anticipate Aridis Pharmaceuticals' share price to reach $15.67 in the next twelve months. This suggests a possible upside of 555.5% from the stock's current price.
View analysts' price targets for Aridis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Aridis Pharmaceuticals' key executives?

Aridis Pharmaceuticals' management team includes the following people:
  • Vu L. Truong, Director, Chief Executive & Scientific Officer (LinkedIn Profile)
  • Fred Kurland, Chief Financial & Accounting Officer
  • Hasan Jafri, Chief Medical Officer
  • Steven M. Chamow, Vice President-Research & Development
  • Lisa Sher, Head-Investor & Public Relations

What other stocks do shareholders of Aridis Pharmaceuticals own?

When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Who are Aridis Pharmaceuticals' major shareholders?

Aridis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (1.24%), Millennium Management LLC (0.62%), BlackRock Inc. (0.35%), Geode Capital Management LLC (0.30%) and Wealth Architects LLC (0.12%). Company insiders that own Aridis Pharmaceuticals stock include John F Hamilton and Vu Truong.
View institutional ownership trends for Aridis Pharmaceuticals
.

Which major investors are selling Aridis Pharmaceuticals stock?

ARDS stock was sold by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC.
View insider buying and selling activity for Aridis Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Aridis Pharmaceuticals stock?

ARDS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Geode Capital Management LLC, Wealth Architects LLC, and BlackRock Inc.. Company insiders that have bought Aridis Pharmaceuticals stock in the last two years include John F Hamilton, and Vu Truong.
View insider buying and selling activity for Aridis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $2.39.

How much money does Aridis Pharmaceuticals make?

Aridis Pharmaceuticals has a market capitalization of $33.59 million and generates $1 million in revenue each year. The company earns $-22.33 million in net income (profit) each year or ($3.79) on an earnings per share basis.

How many employees does Aridis Pharmaceuticals have?

Aridis Pharmaceuticals employs 33 workers across the globe.

What is Aridis Pharmaceuticals' official website?

The official website for Aridis Pharmaceuticals is www.aridispharma.com.

Where are Aridis Pharmaceuticals' headquarters?

Aridis Pharmaceuticals is headquartered at 5941 Optical Ct, San Jose CA, 95138.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The company can be reached via phone at (408) 385-1742, via email at [email protected], or via fax at 408-960-3822.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.